Companies / Kiora Pharmaceuticals, Inc.

Kiora Pharmaceuticals, Inc.

Nasdaq: KPRXCIK 1372514ENCINITAS, CA

Financials · FY2025

Revenue$0
Net income$-10.84M
Total debt$278.2K
Cash$7.08M
Diluted EPS$-2.64
Shares outstanding4.4M

Ownership

4.4M shares outstanding · as of Aug 5, 2026
2.0%Insiders
Ownership
Insiders1.98%87,667
10%+ / strategic8.92%394,668
Institutions15.11%668,381
Public float73.99%3,273,671

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 9

View all →
Insider% of sharesShares
Strem Brian M.CEOPresident and CEO · Director
1.37%60,692
Daniels Eric JosephFormerChief Development Officer
0.72%31,741
0.61%26,975
Parsons ErinDirector
Shapiro AronDirector
Tyle PraveenDirector

Institutional holders 20

View all →

Activity

Jun 30, 2026View all →
InsidersInstitutions
Who's accumulating and trimming this stock (13F).
DateActorActionSecurityValueShares ΔPosition afterImpact
Q1 2026
as of
Geode Capital Management, LLC
13F manager
AddCommon stock$49.9K+26K
+117.40%
47,850
1.08% of shares
low
Q1 2026
as of
Renaissance Technologies LLC
13F manager
ExitCommon stock$-41.8K-21K
-100.00%
0
low
Q2 2026
as of
LPL Financial LLC
13F manager
NewCommon stock$32.9K+13K
12,500
0.28% of shares
low
Q4 2025
as of
Bank of America Corp /De
13F manager
AddCommon stock$8+4
+16.00%
29
<0.01% of shares
low

5%+ ownership events

Schedule 13D / 13G
FilerStance% of classSharesDate
Orin HirschmanPassive13G/A
Rosalind Advisors, Inc.Passive13G/A
Nantahala Capital Partners Limited PartnershipPassive13G/A
Nantahala Capital Management, LLCPassive13G/A
Alyeska Investment Group, L.P.Passive13G394,668

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
KPRX49721T507